Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Pozycja w akcjach #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Cena akcji
$4.74
Ostatnia synchronizacja: 2026-08-31
Kapitalizacja rynkowa
$372.19M
Zmiana (1 dzień)
-2.47%
Zmiana (1 rok)
-1.04%
Kraj
US
Handel Lexeo Therapeutics, Inc. Common Stock (LXEO)

Kategoria

Historia ceny akcji dla Lexeo Therapeutics, Inc. Common Stock (LXEO)
Najwyższa cena zamknięcia: $4.91 dnia 2026-08-01

Najniższa cena zamknięcia: $11.06 dnia 2023-11-01
Historia cen akcji firmy Lexeo Therapeutics, Inc. Common Stock od 2023 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) -31.08%
2025 38.08%
2024 -48.79%
2023 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.37 -11.93%
AU
$138.80 476.17%
US
$745.74 4.52%
CH